Takashi Aiko

Publications (9)20.22 Total impact

• Article: New Japanese classifications and treatment guidelines for gastric cancer: revision concepts and major revised points.

  Takeshi Sano, Takashi Aiko
  Gastric Cancer 06/2011; 14(2):97-100. · 2.42 Impact Factor
• Article: Lipopolysaccharides induced increases in Fas ligand expression by Kupffer cells via mechanisms dependent on reactive oxygen species.

  Keiichiro Uchikura, Tatehiko Wada, Sumito Hoshino, Yuichi Nagakawa, Takashi Aiko, Gregory B Bulkley, Andrew S Klein, Zhaoli Sun
  [show abstract] [hide abstract]
  ABSTRACT: Fas-Fas ligand (FasL)-dependent pathways exert a suppressive effect on inflammatory responses in immune-privileged organs. FasL expression in hepatic Kupffer cells (KC) has been implicated in hepatic immunoregulation. In this study, modulation of FasL expression of KC by endogenous gut-derived bacterial LPS and the role of reactive oxygen species (ROS) as potential mediators of FasL expression in KC were investigated. LPS stimulation of KC resulted in upstream ROS generation and, subsequently, increased FasL expression and consequent Jurkat cell (Fas-positive) apoptosis. The NADPH oxidase and xanthine oxidase enzymatic pathways appear to be major sources of this upstream ROS generation. Increased FasL expression was blocked by antioxidants and by enzymatic blocking of ROS generation. Exogenous administration of H2O2 stimulated KC FasL expression and subsequent Jurkat cell apoptosis. Intracellular endogenous ROS generation may therefore represent an important signal transduction pathway for FasL expression in KC.
  AJP Gastrointestinal and Liver Physiology 10/2004; 287(3):G620-6. · 3.43 Impact Factor
• Article: Configuration of the straight veins and their intramural anastomoses in the human duodenum: an anatomical study using cast specimens.

  Yoichi Hata, Gen Murakami, Mitsuhiro Mukaiya, Toshio Honma, Koichi Hirata, Takashi Aiko
  [show abstract] [hide abstract]
  ABSTRACT: There have, hitherto, been no anatomical investigations of the intramural venous system of the duodenum. Intramural longitudinal anastomoses of the straight veins in the human duodenum were investigated, using 15 latex resin cast specimens. The venous tree (with a straight vein as the trunk) was developed well, with numerous twigs (venules). We identified two types of longitudinal anastomoses between the straight veins; the direct and plexus-mediated types, with an equal incidence. The direct-type anastomosis was 0.1-0.5 mm in minimum diameter along the course and communicated in almost a straight line between the mother straight veins. In contrast, the plexus-mediated type was regarded as the thickest route (almost 0.1 mm) in the suggested submucosal venular network in the duodenal wall. These two types of anastomoses were distributed almost equally in most of the duodenum, although a relatively lower density was found in the superior portion. On the ventral side of the duodenum, the thicker straight veins had anastomotic branches significantly more frequently than the thinner ones (P = 0.0018). CONCLUSIONS; These results seemed to support the feasibility of Kocher mobilization, as well as the conventional poor preservation of the duodenal venous system during duodenum-preserving surgery. However, because the intramural longitudinal venous anastomoses were limited in number and location, we recommend preservation of the posterior superior pancreaticoduodenal vein and either of the inferior venous arcades, in combination with their concomitant arteries, in exchange for the unavoidable sacrifice of Henle's trunk and the dorsal pancreatic vein.
  Journal of Hepato-Biliary-Pancreatic Surgery 02/2003; 10(3):206-14. · 1.60 Impact Factor
• Article: Meeting report of the 72nd Japanese Gastric Cancer Congress.

  Hidenobu Watanabe, Masayoshi Mai, Tadakazu Shimoda, Masae Tatematsu, Atsushi Ochiai, Masaki Mori, Takeshi Sano, Takashi Aiko, Shigeaki Yoshida, Hiroshi Furukawa, Michio Kaminishi, Morio Koike
  Gastric Cancer 09/2000; 3(1):1-8. · 2.42 Impact Factor
• Article: Laparoscopic gastrectomy for advanced cancer: a technical challenge.

  Takashi Aiko
  Gastric Cancer 01/2000; 2(4):199-200. · 2.42 Impact Factor
• Article: Reply to Professor Hermanek's comments on the new Japanese classification of gastric carcinoma.

  Mitsuru Sasako, Takashi Aiko
  Gastric Cancer 06/1999; 2(1):83-85. · 2.42 Impact Factor
• Article: The new Japanese Classification of Gastric Carcinoma: Points to be revised.

  Takashi Aiko, Mitsuru Sasako
  [show abstract] [hide abstract]
  ABSTRACT: SUMMARY OF CHANGES:1. The previous version described clinical, surgical and conclusive staging. This version retains clinical and surgical staging, being the staging before and during definitive surgery respectively. Conclusive staging is now defined as final staging, and may include information for which there is no histological proof (e.g. hepatic metastases). Pathological staging has been introduced, and requires microscopic proof.2. Lymph node staging has been extensively revised. A 3 tier system replaces the previous 4 tier system, and thus there are now 4 possible N stages (N0-3). The definition of some node groupings have been more precisely defined (No.11 and No.12).3. Lymph node dissection is classified D0-3 based on the new nodal groups. Minor modifications of the extent of dissection have been made. "Optional" stations have been omitted.4. Peritoneal cytology has been included in the staging system.6. Rules for staging carcinoma of the remnant stomach have been introduced.7. Rules to classify and evaluate endoscopic mucosal resection (EMR) have been introduced.8. Subclassification of T staging has been introduced for T1 (M and SM) and T2 (MP and SS) tumors.9. Nomenclature has been simplified: lower case letters are only used to define the "type" of staging (c clinical; s surgical; p pathological; f final). Tumor location is now defined as U (upper third), M (middle) or L (lower), replacing C, M, A. Proximal and distal margins are designated as PM and DM (previously OW and AW). LM and VM have been introduced for the lateral and vertical margins of EMR specimens.
  Gastric Cancer 01/1999; 1(1):25-30. · 2.42 Impact Factor
• Article: The new Japanese Classification of Gastric Carcinoma: Points to be revised

  Takashi Aiko, Mitsuru Sasako, see page for list of members of the Japanese Gastric Cancer Association
  [show abstract] [hide abstract]
  ABSTRACT: 1. The previous version described clinical, surgical and conclusive staging. This version retains clinical and surgical staging, being the staging before and during definitive surgery respectively. Conclusive staging is now defined as final staging, and may include information for which there is no histological proof (e.g. hepatic metastases). Pathological staging has been introduced, and requires microscopic proof. 2. Lymph node staging has been extensively revised. A 3 tier system replaces the previous 4 tier system, and thus there are now 4 possible N stages (N0-3). The definition of some node groupings have been more precisely defined (No.11 and No.12). 3. Lymph node dissection is classified D0-3 based on the new nodal groups. Minor modifications of the extent of dissection have been made. "Optional" stations have been omitted. 4. Peritoneal cytology has been included in the staging system. 6. Rules for staging carcinoma of the remnant stomach have been introduced. 7. Rules to classify and evaluate endoscopic mucosal resection (EMR) have been introduced. 8. Subclassification of T staging has been introduced for T1 (M and SM) and T2 (MP and SS) tumors. 9. Nomenclature has been simplified: lower case letters are only used to define the "type" of staging (c clinical; s surgical; p pathological; f final). Tumor location is now defined as U (upper third), M (middle) or L (lower), replacing C, M, A. Proximal and distal margins are designated as PM and DM (previously OW and AW). LM and VM have been introduced for the lateral and vertical margins of EMR specimens.
  Gastric Cancer 01/1998; 1(1):25-30. · 2.42 Impact Factor
• Article: Perioperative detection of circulating cancer cells in patients with colorectal hepatic metastases.

  Keiichiro Uchikura, Shinichi Ueno, Sonshin Takao, Futoshi Miyazono, Saburo Nakashima, Koki Tokuda, Akihiro Nakajo, Masataka Matsumoto, Takashi Aiko
  [show abstract] [hide abstract]
  ABSTRACT: Surgical resection is the most effective therapy for metastatic colorectal cancer to the liver. However, the selection criteria for patients who may benefit from partial hepatectomy are not fully defined. The aim of this study was to evaluate the usefulness of perioperative molecular detection of circulating cancer cells in predicting clinical outcome in patients with colorectal metastatic liver cancer. Blood samples were obtained perioperatively from the portal vein, peripheral artery, and superior vena cava in 16 consecutive patients with colorectal liver metastases who have undergone partial hepatic resection. We analyzed circulating cancer cells using a carcinoembryonic antigen-specific nested reverse transcriptase-polymerase chain reaction. Positive carcinoembryonic antigen-mRNA expression was detected in 7 (43.8%) of 16 patients. Six (85.7%) of those 7 patients had hematogenous rerecurrences during the 1- to 3-year follow-up period. None of 9 negative-patients showed re-recurrence (p < 0.01). Among the 9 of 16 patients receiving postoperative adjuvant chemotherapy, no clear effect was noted regarding re-recurrence in the positive carcinoembryonic antigen-mRNA patients. These results suggest that the molecular detection of circulating cancer cells at the time of surgery for colorectal liver metastases could be one measure of high-risk patients for hematogenous re-recurrence after partial hepatic resection.
  Hepato-gastroenterology 49(48):1611-4. · 0.66 Impact Factor